Unveiling the therapeutic potential of Farnesol against Parkinson's disease: insights from molecular Docking and animal studies.

Background: Parkinson's disease (PD) is a chronic neurodegenerative disorder that progressively worsens over an individual's lifetime. Current treatments primarily address the symptoms rather than the underlying cause of the disease, and many patients report adverse side effects from the medications...

Descripción completa

Detalles Bibliográficos
Publicado en:DARU: Journal of Pharmaceutical Sciences Vol. 34; no. 1; pp. 1 - 14
Autores principales: Baishya, Hirok Jyoti, Nargish, Jyutia, Sola, Piyong
Formato: pictorial research tables/charts Journal Article
Publicado: Springer Nature 2/14/2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=194161801&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 194161801
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        15608115
        8WS
      jtl: DARU: Journal of Pharmaceutical Sciences
      issn: 15608115
      maglogo: N
    pubinfo:
      dt: 2/14/2026
      vid: 34
      iid: 1
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        194161801
        194161801
        194161801
        10.1007/s40199-026-00592-3
        194161801
      ppf: 1
      ppct: 13
      formats:
      tig:
        atl: Unveiling the therapeutic potential of Farnesol against Parkinson's disease: insights from molecular Docking and animal studies.
      aug:
        au:
          Baishya, Hirok Jyoti
          Nargish, Jyutia
          Sola, Piyong
        affil: https://ror.org/02t3qn464 Department of Pharmacology, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Shantipur, Mirza, Kamrup, India
      sug:
        subj:
          Parkinson Disease Drug Therapy
          Hydrocarbons Pharmacodynamics
          Hydrocarbons Therapeutic Use
          Phytochemicals
          Basil Pharmacodynamics
          Plant Extracts Pharmacodynamics
          Molecular Docking Simulation Methods
          Neuroprotective Agents Pharmacodynamics
          Animal Studies
          Mice
          In Vivo Studies
          Isoflavones
          Oxidative Stress Drug Effects
          Data Analysis Software
          Descriptive Statistics
          Two-Way Analysis of Variance
          One-Way Analysis of Variance
          Post Hoc Analysis
          Comparative Studies
          Superoxide Dismutase
          Lipid Peroxidation
          Malondialdehyde
          India
          Models, Biological
          Behavioral Changes Drug Effects
          Blood-Brain Barrier
      ab: Background: Parkinson's disease (PD) is a chronic neurodegenerative disorder that progressively worsens over an individual's lifetime. Current treatments primarily address the symptoms rather than the underlying cause of the disease, and many patients report adverse side effects from the medications used. Nature offers a wealth of medicinal plants, among which Ocimum tenuiflorum stands out for its potential to treat various health issues. Objective: The objective of the study is to identify an effective phytochemical from Ocimum tenuiflorum using in silico and in vivo methods for the management of PD. Methods: Molecular docking was employed to identify potential phytochemicals in Ocimum tenuiflorum that target the mTOR pathway. Farnesol was chosen for further evaluation based on its docking score, blood-brain barrier permeability, and pharmacokinetic properties. In vivo studies were carried out using rotenone-induced PD models in mice, and the effects of farnesol on behavioral changes, oxidative stress, and histopathological alterations were examined. Results: Farnesol showed a high docking score and the ability to cross the blood-brain barrier. In vivo studies revealed that farnesol treatment enhanced locomotor activity, lowered cataleptic scores, and increased antioxidant enzyme activity (SOD) in the brain. The strongest antioxidant effect was achieved by the high dose, which brought the levels of MDA and SOD near to the control 8.3% and 95.4% respectively, as compared to the disease group. Additionally, farnesol decreased lipid peroxidation levels and protected against neuronal damage in the substantia nigra region. Conclusion: Farnesol exhibits significant neuroprotective effects in rotenone-induced PD models, suggesting its potential as a therapeutic candidate for managing PD.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N